Document is current
Any future updates will be listed below
-
Authors
Borruto, Anna Maria https://orcid.org/0000-0002-0953-8865
Coppola, Andrea
Höglund, Leon
Eriksson Solander, Sandra
Petrella, Michele
Heilig, Markus https://orcid.org/0000-0003-2706-2482
Augier, Eric https://orcid.org/0000-0002-5615-2973
-
Funding
Funding for this research was provided by:
Vetenskapsrådet (VR project number 2018-02320)
Vetenskapsrådet (VR project number 2023-02186)
- License Information
-
More Information
Article History
Received: 7 May 2025
Revised: 11 December 2025
Accepted: 20 January 2026
First Online: 29 January 2026
Competing interests
: Eric Augier serves as Principal Investigator on a research contract with Indivior Inc., aimed at evaluating novel candidates for AUD. Markus Heilig has received research funding or consulting fees in the past 5 years from Aelis Farma, Brainsway Technologies, Camurus, Indivior, Janssen, Molteni, Nordic Drugs, and Pfizer. These contracts are unrelated to the present work. The authors declare no other biomedical financial interests or potential conflicts of interest.
